Herewith three items of pandemic news you may have missed recently: Pfizer gets permission to ship fewer vials; how non-pharmaceutical interventions have varied over the course of the pandemic; and how vaccines are coping with the new virus variants. Plus … Continue reading →
Minnesota has refined its pilot program for people over 65 to get access to far too few doses of vaccine. This week it’s a lottery. Last week’s first-come, first-served free-for-all resulted in several hundred thousand frustrated and disappointed Minnesotans (present … Continue reading →
Herewith three items of pandemic news you may have missed recently: More on virus variants; Novavax’s Phase III study is leaking volunteers; and vaccine hesitancy in the Black population. Plus news briefs and a frippery. Black vaccine hesitancy For all … Continue reading →
Herewith three items of pandemic news you may have missed recently: Booking a shot in Minnesota; low dead-space syringes; and Norway is investigating the deaths of elderly vaccine recipients. Plus news briefs and a frippery. Norway urges caution before vaccinating … Continue reading →
Herewith three items of pandemic news you may have missed recently: Llama antibodies redux; two new viral variants out of Ohio; and the function of that second shot of vaccine. Plus news briefs and a frippery. What the second shot … Continue reading →
Herewith three items of pandemic news you may have missed recently: Infected gorillas; inhalable therapies and prophylactics; and the greater difficulty of testing new vaccine candidates once some have been authorized. Plus the accustomed frippery. After authorized vaccines, testing later … Continue reading →
Herewith three items of pandemic news you may have missed recently: Pfizer’s vaccine handles the UK variant just fine; how to go about producing a vaccine-evading coronavirus; and Biden will not hold back second doses. Plus the accustomed frippery. Biden … Continue reading →
Herewith three items of pandemic news you may have missed recently: A particular risk of diabetes with Covid-19; worries of vaccine escape by the South African variant; and the many ideas floated for bolstering vaccine supply. Plus a frippery. Ways … Continue reading →
Herewith three items of pandemic news: the UK variant seems to spread faster in the young; what’s next in vaccines (by new contributor Doug Pardee); and the import of the PCR test cycle threshold. Plus the accustomed frippery. Cycle threshold … Continue reading →
Not only has the UK approved the AstraZeneca / Oxford vaccine candidate, on what many specialists consider thin evidence from a bungled trial, they are embarking on a grand epidemiological experiment: seeing how well covering more people with a single … Continue reading →
Herewith three items of pandemic news you may have missed recently: psychotic sequelae to Covid-19; Novavax’s Phase III begins in the US; and as we move into year 2, what we may choose to forget. Plus the usual frippery. What … Continue reading →
Herewith three items of pandemic news you may have missed recently: Less accurate pulse oximeter readings for Black patients; the spreading mink pandemic; and a marketing name for the Pfizer / BioNTech vaccine. Plus the accustomed frippery. Comirnaty You may … Continue reading →
Herewith three items of pandemic news you may have missed recently: FDA investigating allergic reactions to the first vaccine; the susceptibility of pigs; and the give-and-take among sleep, melatonin, and Covid-19. Plus the usual frippery. Sleep The Atlantic has a … Continue reading →
A CDC advisory committee has issued its recommendation for prioritizing who is next to receive scarce Covid-19 vaccines. Those over 75 and some first responders are up next, followed by over-65s, more essential workers, and younger adults with preconditions. The … Continue reading →
In England and in South Africa, researchers are warning about new variants of the SARS-CoV-2 virus that are spreading rapidly in those countries. Both involve an unusually high number of mutations, including to the spike protein. For this story, which … Continue reading →
